David A. Siegel Ultragenyx Pharmaceutical Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 448,200 shares of RARE stock, worth $18.4 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
448,200
Previous 188,900
137.27%
Holding current value
$18.4 Million
Previous $9.03 Million
131.66%
% of portfolio
0.05%
Previous 0.02%
Shares
14 transactions
Others Institutions Holding RARE
# of Institutions
286Shares Held
78.6MCall Options Held
570KPut Options Held
228K-
Vanguard Group Inc Valley Forge, PA8.7MShares$358 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.09MShares$291 Million5.31% of portfolio
-
Black Rock Inc. New York, NY5.24MShares$215 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA4.1MShares$168 Million0.03% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.86MShares$159 Million0.53% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.88B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...